Taysha Gene Therapies
TSHA
TSHA
71 hedge funds and large institutions have $111M invested in Taysha Gene Therapies in 2022 Q1 according to their latest regulatory filings, with 15 funds opening new positions, 27 increasing their positions, 15 reducing their positions, and 9 closing their positions.
New
Increased
Maintained
Reduced
Closed
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding
Funds holding: →
less ownership
Funds ownership: →
34% less call options, than puts
Call options by funds: $108K | Put options by funds: $163K
49% less capital invested
Capital invested by funds: $215M → $111M (-$105M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Holders
71
Holding in Top 10
–
Calls
$108K
Puts
$163K
Top Buyers
| 1 | +$1.63M | |
| 2 | +$1.32M | |
| 3 | +$1.12M | |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$838K |
| 5 |
Two Sigma Investments
New York
|
+$735K |
Top Sellers
| 1 | -$13.4M | |
| 2 | -$6.43M | |
| 3 | -$5.47M | |
| 4 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
-$797K |
| 5 |
Millennium Management
New York
|
-$700K |